ClinicalTrials.gg
RecruitingNCT06204094CASINOsUpdated Apr 24, 2026

Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

A Phase 2 interventional study of node-sparing short-course radiotherapy and Sintilimab in Locally Advanced Rectal Cancer, sponsored by Jinhua Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Jinhua Central Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing sintilimab in Rectal Neoplasms — 13 open to participants now, 16 under way, 5 of them phase 3. sintilimab · Rectal Neoplasms.

Planned enrollment
14th of 19
37 · median 50
Started
2024
with 3 others
Phase 2
10 of 19
5 open now
Primary completion
2027-09
later than 5 of 15 live
Registered
6th of 19
by date
Lead sponsor
1 of 19
Jinhua Central Hospital

Among the 19 studies testing sintilimab in Rectal Neoplasms, this one is the 14th largest by planned enrollment, is one of 4 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 5 of the 15 other live ones, and was the 6th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

13 of the 19 studies testing sintilimab in Rectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing sintilimab in Rectal Neoplasms, or all of them as a file.
02

Study summary

phase II clinical trial to evaluate node-sparing short-course radiation combined with total neoadjuvant CAPOX and Sintilimab for MSS locally advanced rectal cancers.

Read the detailed description

This is an open-label, prospective, single-center phase II clinical trial to evaluate node-sparing short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with total neoadjuvant CAPOX and PD-1 Inhibitor (Sintilimab) for patients with MSS locally advanced of middle and low rectal cancer. A total of 37 patients will be enrolled in this trial. The primary endpoint is the complete response(CR) rate, which includes cCR and pCR. The organ preservation rate, tumor regression grade, 3-year DFS, 3-year OS, and adverse effects will also be analyzed.

03

Conditions studied

  • Locally Advanced Rectal Cancer

Browse trials for

Keywords

  • rectal cancer
  • microsatellite stability
  • node-sparing
  • CAPOX
  • radiotherapy
  • sintilimab
  • immunotherapy
  • neoadjuvant
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have a strong willingness to preserve the anus and are willing to receive therapy.
  • Male or Female aged 18-75.
  • Patients diagnosed with low rectal cancer within 10 cm from the lower edge of the tumor to the anal verge by pelvic MRI and anorectoscopy, the clinical stage is cT2N+M0/cT3-4N0/+M0, the lymph nodes are limited to the mesorectum.
  • confirmed rectal adenocarcinoma; Genetic testing suggests MSI-L or MSS, or tumor immunohistochemistry reveals pMMR, that is, MSH1, MSH2, MSH6, and PMS2 are all positive.
  • (ECOG) 0-1.
  • No previous treatment(including anti-tumor therapy、immunotherapy or pelvic radiation).
  • Adequate hematologic, hepatic, renal, thyroid and cardiac function: white blood cells ≥3500/mm3, neutrophils ≥1800/mm3, ≥100,000/mm3, ≥100 g/L; , prothrombin time and international normalized ratio ≤1.5 × ; and alanine aminotransferase ≤3.0 × upper limit of normal (ULN), ≤1.25 × ULN, serum albumin ≥28 g/L. ≥50 mL/mi, creatinine ≤1.5 × ULN;
  • form signed.

Exclusion criteria

Exclusion Criteria:

  • Patients with a previous history of malignant tumors besides rectal cancer.
  • Patients with distant before enrollment.
  • Patients with positive internal or external iliac lymph nodes are assessed by MRI or CT.
  • Patients with obstruction, perforation, or bleeding that require emergency surgery.
  • Patients with severe concomitant diseases and estimated survival time ≤ 5 years.
  • Allergic to any component of the therapy.
  • Patients with poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous adenocarcinoma.
  • Patients who received or systemic hormone therapy for immunosuppressive purposes within 1 month prior to the initiation of therapy.
  • Patients who have received any other experimental drug (including immunotherapy) or participated in another interventional clinical trial within 30 days before screening.
  • Factors leading to study termination, such as alcoholism, drug abuse, other serious illnesses (including psychiatric disorders) requiring combination therapy, and patients with severe laboratory abnormalities.
  • Patients with congenital or acquired immune deficiency (such as infection).
  • Vulnerable groups, including mentally ill, cognitively impaired, critically ill patients, minors, pregnant or lactating women, illiterate, etc.

Other conditions that investigators consider not suitable for this study.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Participants will receive 5\*5Gy node-sparing short-course radiation (radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) concurrently with total neoadjuvant CAPOX and sintilimab regimens: Oxaliplatin, 130mg/m2, intravenous infusion,d1 of each cycle; Capecitabine, 1000mg/m2, PO, BID, d1-14 and sintilimab, 200mg intravenous infusion d1 of each cycle. CAPOX and sintilimab are repeated every 3 weeks for 6 cycles. Patients with cCR will be managed with a WW strategy, and patients who did not achieve cCR will receive TME surgery. Interventions: * Radiation: node-sparing short-course radiation * Drug: PD-1 antibody (Sintilimab) * Drug: Capecitabine * Drug: Oxaliplatin

    Radiation: node-sparing short-course radiotherapy · Drug: Sintilimab · Drug: Capecitabine · Drug: Oxaliplatin · Procedure: TME surgery · Procedure: watch and wait

Interventions

  • Radiationnode-sparing short-course radiotherapy

    5Gy\*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes

  • 200mg intravenous infusion d1 of each cycle\*6cycles

    Also known as: IBI308

  • 1000mg/m2, PO, BID, d1-14 of each cycle\*6cycles

  • 130mg/m2, intravenous infusion,d1 of each cycle\*6cycles

  • ProcedureTME surgery

    laparoscopic or robotic TME surgery for non-cCR patients

    Also known as: total mesorectal excision

  • Procedurewatch and wait

    WW for cCR patients

    Also known as: WW

06

What researchers measure

Primary outcomes

  1. Complete response

    Pathological complete response (pCR) :absence of residual tumour on resected specimen. Clinical complete response(cCR): no residual tumour visible on imaging or colonoscopy and biopsy.

    Time frame: within 10 days after TNT therapy or surgery

Secondary outcomes

  1. Tumor regression grade

    TRG is evaluated according to the AJCC system. TRG0-1 is defined as good response, TRG2 as moderate response, and TRG3 as poor response.

    Time frame: within 10 days after surgery

  2. Local recurrence rate(LRR)

    Presence of adenocarcinoma within the rectal wall or within the mesorectum confirmed by pathology.

    Time frame: 3 years after sugery

  3. Disease free survival(DFS)

    the time from randomization to recurrence of tumor or death

    Time frame: 3 years after treatment

  4. Overall survival(OS)

    the time from randomization to death

    Time frame: 3 years after enrollment

  5. Adverse effects rate

    Rate of radiotherapy, chemotherapy and immunotherapy related adverse events

    Time frame: From date of initiation of treatment until the date of death from any cause, assessed up to 5 years

  6. Rectal specific quality of life assessment via QLQ-CR29

    Rectal specific quality of life according to European Organization for Research and Treatment of Cancer ( EORTC) Quality of life questionnaire QLQ-CR29. scale from 0 to 100, A higher scale represents better function and a higher quality of life.

    Time frame: Baseline and months 3, 6, 12, 24, 36, 60 after the TNT treatment or surgery

  7. Quality of life assessment via QLQ-C30

    Quality of life according to EORTC Quality of life Questionnaire QLQ-C30 version 3.0. Score range from 0 to 100 points. A higher score represents better function and a higher quality of life.

    Time frame: Baseline and months 3, 6, 12, 24, 36, 60 after the TNT treatment or surgery

  8. Validation of the Wexner score

    The change of severity of fecal incontinence assessment according to Wexner score. a score from 0-20, where 0 is perfect continence and 20 is complete incontinence.

    Time frame: Months 3, 6, 12, 24, 36, 60 after the TNT treatment or surgery

07

Study locations

1 of 1 sites recruiting
  • Zhejiang University Affiliated Jinhua Hospital
    Jinhua, Zhejiang 0579, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — JinhuaCH will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: inhuaCH will consider access to study data upon a written detailed request sent to JinhuaCH, from 6 months until 5 years after publication of summary data.

Access criteria: The data shared will be limited to that required for independent mandated verification of the published results, the applicant will need authorization from JinhuaCH for personal access, and the data will only be transferred after signing of a data access agreement.

Data sharing details ↗ · www.jhzxyy.cn

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Sep 2027, 42 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 42 months is below that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2024
First posted
Jan 12, 2024
StartActual
Feb 5, 2024
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2028
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06204094
Lead sponsor
Jinhua Central Hospital
Responsible party
Cheng Cai (Clinical Professor, Jinhua Central Hospital) — Principal investigator
First posted
Jan 12, 2024
Start date
Feb 5, 2024
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Apr 24, 2026

Study contacts

jinlin du, master
Contact
djl9090@163.com
86 13957998111
cheng cai, master
Contact
ColoSurg_cc@zju.edu.cn
86 18395995912

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion